Oral terbinafine was first introduced in the United Kingdom in Februar
y 1991 and was approved for the treatment of onychomycosis in the Unit
ed States in May 1996. It is estimated that 4 million patients worldwi
de have been treated with oral terbinafine as of December 1996. The ef
ficacy of terbinafine in the treatment of onychomycosis and other derm
atomycoses is reviewed. The adverse-effects profile of oral terbinafin
e is evaluated.